| 摘要 |
<p><P>PROBLEM TO BE SOLVED: To perform treatment of diseases whose pathophysiological mechanism is based on insulin resistance, and treatment of hypertension, with superior efficacy, action intensity and low toxicity. <P>SOLUTION: There is provided a new crystalline form of potassium 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione of formula (I). There are also provided pharmaceutical compositions comprising the new crystalline form and a pharmaceutically permissible carrier. The new crystalline form is more active than conventional potassium 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione, as an antidiabetic agent. <P>COPYRIGHT: (C)2011,JPO&INPIT</p> |
